Treatment with valproic acid (VPA) enhanced cisplatin sensitivity of non-small-cell lung cancer (NSCLC) cells via HDAC2 mediated down-regulation of ABCA1, further reinforcing the idea that overexpression of ABCA1 in lung cancer can be associated with resistance to therapies [31]. The gene discussed is ABCA1; the disease is lung cancer.